In the first week of 2022, the administration of the US Food and Medicine (FDA) ratified the use of a single booster shot Pfizer-Biontech Covid-19 for individuals between ages 12 and 15 years. The federal body has now lowered the age bracket for the subjects who meet the requirements for booster shots. In renewing the rules of the Emergency Use Authorization (EUA) governing the Pfizer-Biontech Covid-19 vaccine, FDA a.s. has announced that individuals 5 years or more can also make booster shots managed for additional protection against SARS-COV-2 viruses.
In a press release, the agency said that “individuals 5 to 11 years at least five months after completing the primary series” Covid-19 vaccine rounds meet the requirements to get a booster shot. FDA a.s. notes that the vaccination policy update came after the ongoing random placebo controlled trial which resulted in a positive antibody response to the injection of the booster for participants who received seven to nine months after completing the primary vaccination series two doses of two doses of the Pfizer-Biontech Covid-19 vaccine.
Fortify the shield of Covid-19 for children
To test the efficacy of the PFizer-Biontech Covid-19 vaccine booster dose for children aged between 5 and 11 years, this agency monitors 400 children who receive it anywhere between five to nine months after a series of main doses involved in two blows. Coming to the side effects of the booster shot, FDA U.S. Include fatigue, headache, cold, fever, muscle or joints, pain, swelling, and redness at the injection site.
Speaking of the decision, FDA Commissioner Robert M. Califf noted that more children fell ill and were hospitalized in Omicron waves, complete with the risk of long-term effects on the body’s system even after mild disease. With an official nod for the administration of a single booster dose of the Pfizer-Biontech Covid-19 vaccine to children aged 5 years, this agency aims to provide a stronger defense line against Covid-19.
Pfizer, on the other hand, estimates that more than 8 million children in the age group 5 to 11 have completed a series of main COVID-19 vaccination and qualified for booster shots. Citing data from clinical trials, the company claims that the booster dose of the Pfizer-Biontech Covid-19 vaccine can produce antibodies that can neutralize the Omicron variant and the wild type COVID-19 virus.